Sanofi (SNY) P/E Ratio History
Historical price-to-earnings valuation from 2013 to 2025
Loading P/E history...
SNY Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Sanofi (SNY) trades at a price-to-earnings ratio of 18.4x, with a stock price of $43.77 and trailing twelve-month earnings per share of $3.20.
The current P/E is roughly in line with its 5-year average of 19.3x. Over the past five years, SNY's P/E has ranged from a low of 10.2x to a high of 31.7x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, SNY trades at a 17% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, SNY trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SNY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SNY P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $154B | 12.7 | 0.61 | +2% | |
| $287B | 28.3 | 1.30 | +191% | |
| $283B | 20.6 | 1.34 | +22% | |
| $102B | 6.7Lowest | 0.47Best | +348%Best | |
| $151B | 19.5 | - | -4% | |
| $280B | 15.6 | 0.73 | +8% | |
| $933B | 43.0 | 1.49 | +96% | |
| $363B | 86.5 | - | -1% | |
| $115B | 16.4 | - | +178% | |
| $541B | 38.8 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SNY Historical P/E Data (2013–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $48.46 | $2.04 | 23.8x | +0% |
| FY2025 Q3 | $47.20 | $3.85 | 12.3x | -48% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $48.31 | $3.84 | 12.6x | -47% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $55.46 | $2.69 | 20.6x | -13% |
| FY2024 Q4 | $48.23 | $2.39 | 20.2x | -15% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $57.63 | $1.82 | 31.7x | +34% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $48.52 | $1.69 | 28.7x | +21% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $48.60 | $1.81 | 26.9x | +13% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $49.73 | $2.15 | 23.1x | -2% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $53.64 | $3.61 | 14.9x | -37% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $53.90 | $3.44 | 15.7x | -34% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $54.42 | $3.34 | 16.3x | -31% |
Average P/E for displayed period: 23.7x
Full SNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNY — Frequently Asked Questions
Quick answers to the most common questions about buying SNY stock.
Is SNY stock overvalued or undervalued?
SNY trades at 18.4x P/E, near its 5-year average of 19.3x. The 40th percentile ranking places valuation within normal historical bounds.
How does SNY's valuation compare to peers?
Sanofi P/E of 18.4x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is SNY's PEG ratio?
SNY PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2025.